About
About SELLAS Life Sciences Group, Inc
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.
Visit company website
5 years, 4 months ago
SELLAS Life Sciences Group, Inc is currently in a long term uptrend where the price is trading 17.1% above its 200 day moving average.
From a valuation standpoint, the stock is 97.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 36.3.
SELLAS Life Sciences Group, Inc's total revenue rose by inf% to $2M since the same quarter in the previous year.
Its net income has increased by 49.9% to $-4M since the same quarter in the previous year.
Finally, its free cash flow grew by 182.0% to $3M since the same quarter in the previous year.
Based on the above factors, SELLAS Life Sciences Group, Inc gets an overall score of 5/5.